MI
Michigan Bill Would Require Attorney General to Report on Insulin Drug Pricing
Michigan House Bill 6132 would amend the state's Consumer Protection Act to add a new section requiring the Department of Attorney General to produce a report on insulin drug pricing. The bill is framed as a consumer protection measure aimed at increasing transparency around the cost of insulin in Michigan. The bill was electronically reproduced in late June 2026 and is in early stages of the legislative process.
✓ REASONS TO SUPPORT
- A required report could shine a light on whether insulin prices in Michigan are fair, giving consumers and lawmakers better information to act on
- Placing this reporting duty under the Consumer Protection Act signals that insulin pricing is a serious concern for Michigan families who depend on the drug
- Greater transparency on pricing could help identify whether unfair trade practices are driving up costs for people with diabetes
- The report could provide a foundation for future legislative action if pricing problems are found
✕ REASONS TO OPPOSE
- A report alone does not directly lower insulin prices or provide immediate relief to Michigan residents struggling with costs
- Requiring the Attorney General's office to produce this report could divert staff time and resources from other consumer protection priorities
- The bill does not specify what the report must contain or what happens after it is released, which may limit its real-world impact
- State-level reporting may have little effect on insulin pricing, which is largely determined by federal regulations and national pharmaceutical market dynamics
Read the full bill ↗
Send a postcard to your representatives